Enhancing the invasive traits of breast cancers by CYP1B1 via regulation of p53 to promote uPAR expression

• Published in: Biochimica et biophysica acta. Molecular basis of disease Vol. 1870; no. 1; p. 166868
• Main Authors: Kwon, Yeo-Jung, Kwon, Tae-Uk, Shin, Sangyun, Lee, Boyoung, Lee, Hyein, Park, Hyemin, Kim, Donghak, Moon, Aree, Chun, Young-Jin
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 01.01.2024
• Subjects: CYP1B1; Invasive traits; Phosphorylation; Relapse-free survival of breast cancer patients; uPAR; Wildtype/oncogenic mutant p53; Wildtype/oncogenic mutant p53; CYP1B1; Phosphorylation; uPAR; Relapse-free survival of breast cancer patients; Invasive traits
• ISSN: 0925-4439; 1879-260X
• DOI: 10.1016/j.bbadis.2023.166868

Human cytochrome P450 1B1 (CYP1B1) catalyzes estrogen metabolism to produce metabolites that promote the progression of breast cancer. Since the invasive properties of cancer cells cause cancer relapse, which dramatically reduces patient survival, we investigated the new pro-invasive mechanism involving CYP1B1 in breast cancer. Exploring clinical data from invasive breast cancer patients revealed that CYP1B1 exhibits a potential correlation with urokinase-type plasminogen activator receptor (uPAR). Interestingly, uPAR mRNA expression was elevated in invasive breast cancer patients carrying TP53 genes with driver mutations, and our results showed that CYP1B1 activates the uPAR pathway following regulation of p53 according to its mutant status. CYP1B1 suppressed wild-type (WT) p53 whereas it induced the oncogenic gain-of-function mutant p53R280K, not only via transcriptional regulation but also the protein stabilization and activation following phosphorylation on Ser15 residue of p53R280K. Intriguingly, results from CYP1B1 polymorphic gene study and 4-hydroxyestradiol (4-OHE2) treatment showed that CYP1B1 regulates p53s and uPAR through its enzymatic activity. Furthermore, effects of DMBA and TMS on uPAR expression disappeared in HCT116p53−/− cells, indicating that p53 is critical for uPAR induction by CYP1B1. Collectively, our results demonstrate that CYP1B1 may reduce the relapse-free survival rate of breast cancer patients by inducing invasive traits in cancer cells via p53 regulation based on the mutation status of TP53 genes and further activation of the uPAR pathway. The elucidation of the previously unknown molecular mechanism of CYP1B1 may provide evidence for the development of effective anti-cancer therapeutic strategies that target the progression of cancer invasion. Actions of CYP1B1 for induction of uPAR expression and activation of uPAR pathway depending on the mutation status of p53. Schemes describing the findings of our study. CYP1B1 induces breast cancer cell invasion through activation of uPAR pathway via upregulation of uPAR expression. Induction of uPAR expression by CYP1B1 is executed differently according to the mutation status of p53 genes; CYP1B1 suppresses the expression level and phosphorylation level at Ser15 of WT p53 in MCF-7 cells, whereas it promotes the expression level and phosphorylation level at Ser15 of oncogenic mutant p53R280K in MDA-MB-231 cells. [Display omitted] •Human CYP1B1 reduces the relapse-free survival rate of patients with breast cancer.•CYP1B1 activates uPAR signaling pathway through induction of uPAR expression to stimulate breast cancer cell invasion.•CYP1B1 induces the promoter activity of uPAR through regulation of wild-type/oncogenic mutant p53R280K.•CYP1B1 regulates wild-type/oncogenic mutant p53R280K by its enzymatic activity to generate 4-hydroxyestradiol.•Combination therapy targeting CYP1B1 and oncogenic mutant p53 may offer a promising effect for cancer treatment.